Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
06:22:27 EDT Sun 20 Apr 2025
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

Q:ZVRA - ZEVRA THERAPEUTICS INC - Website unknown - click to update
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
ZVRA - Q0.17.15·7.170.17.15+0.101.4406.16.98  7.27  6.899.75  4.20Apr 17Apr 1715 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-04-17 07:30U:ZVRANews ReleaseZevra Announces Publication of MIPLYFFA(TM) Mechanism of Action Manuscript in Molecular Genetics and Metabolism
2025-04-07 07:30U:ZVRANews ReleaseZevra Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $150 Million
2025-03-31 16:12U:ZVRANews ReleaseZevra Therapeutics Files Preliminary Proxy
2025-03-11 16:05U:ZVRANews ReleaseZevra Reports Full Year 2024 and Fourth Quarter Financial Results
2025-02-28 07:30U:ZVRANews ReleaseZevra Launches New Disease State Awareness Campaign, 'Learn NPC, Read Between the Signs,' to Drive Early Recognition and Treatment of Niemann-Pick Disease Type C
2025-02-27 07:31U:ZVRANews ReleaseZevra Therapeutics Enters Agreement to Sell its Rare Pediatric Disease Priority Review Voucher for $150 Million
2025-02-26 09:46U:ZVRANews ReleaseZevra to Report 2024 Fourth Quarter and Full Year Financial Results
2025-02-24 16:02U:ZVRANews ReleaseZevra to Participate at Upcoming Investor Conferences
2025-01-30 07:30U:ZVRANews ReleaseZevra Therapeutics to Present at the 21st Annual WORLDSymposium(TM)
2025-01-29 16:05U:ZVRANews ReleaseZevra Therapeutics to Participate at Upcoming Investor Conferences
2024-12-17 07:30U:ZVRANews ReleaseZevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
2024-12-06 17:00U:ZVRANews ReleaseZevra Therapeutics Announces Organizational Changes
2024-11-26 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate at Upcoming Investor Conferences
2024-11-21 16:52U:ZVRANews ReleaseZevra Therapeutics Announces U.S. Commercial Availability of MIPLYFFA(TM) (arimoclomol) for Treatment of Niemann-Pick Disease Type C
2024-11-12 16:05U:ZVRANews ReleaseZevra Therapeutics Reports Third Quarter 2024 Financial Results and Corporate Updates
2024-11-11 16:37U:ZVRANews ReleaseZevra Therapeutics to Present Data Demonstrating Relevance of Swallow Domain in Niemann-Pick Disease Type C Clinical Severity Scale at 53rd Child Neurology Society Annual Meeting
2024-11-06 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate at the Guggenheim Securities Healthcare Innovation Conference on Wed, Nov. 13
2024-10-31 07:30U:ZVRANews ReleaseZevra Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Nov. 12, 2024
2024-10-10 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate in Rare Disease Panel at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC
2024-10-09 09:00U:ZVRANews ReleaseNUCDF and Zevra Therapeutics Launch Check Ammonia Campaign to Highlight Critical Importance of Prompt, Accurate Blood Ammonia Testing for Diagnosing Urea Cycle Disorders